FDA Panel Votes in Favor of Nirsevimab for RSV Disease Prevention in Infants
If approved by the third quarter of 2023, the Company expects to make nirsevimab available for the 2023 to 2024 RSV season.
House Dust Mite Sublingual Immunotherapy Tablet Effective in Pediatric Patients
The study included 1458 children aged 5 to 11 years with a clinical history of HDM-induced allergic rhinitis.
MPR Weekly Dose Podcast #163
FDA revoke Emergency Use Authorization for COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients.
Almost All Blood Donors Had SARS-CoV-2 Antibodies by Third Quarter of 2022
47.7 percent of those ≥16 years had hybrid immunity, with the lowest prevalence seen for adults aged ≥65 years.
Water-Free Dry Eye Disease Therapy Vevye Gets FDA Approval
Vevye is cyclosporine, solubilized in a novel, water-free excipient.
Pembrolizumab Plus Chemotherapy Under Review for Biliary Tract Cancer
The sBLA is supported by data from the KEYNOTE-966 trial.
Gene Therapy Gets Fast Track, Orphan Drug Status for PKP2 Arrhythmogenic Cardiomyopathy
RP-A601 is an investigational adeno-associated virus-based gene therapy.
RECELL System Approved to Treat Full-Thickness Skin Defects
The RECELL System is a single-use, autologous cell harvesting device.
Cancer Vaccine mRNA-4157 Improves RFS, DMFS in High-Risk Melanoma
Adding the mRNA-4157 vaccine to pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk, resected melanoma in a phase 2 trial.
Chemotherapy Shortage Affecting More Than 90% of NCCN Cancer Centers Surveyed
Most NCCN cancer centers have been affected by shortages of the chemotherapy drugs carboplatin and cisplatin, a survey suggests.
- Loading...
